Key result
Disodium cromoglycate reduces neointimal hyperplasia after arterial injury in mice.
Why the study?
The study investigated the role of mast cells in post-endothelial injury inflammation and evaluated whether mast cell stabilization could serve as a target for therapy.
Does disodium cromoglycate (DSCG) reduce neointimal hyperplasia in mice following arterial injury?
Does disodium cromoglycate (DSCG) reduce neointimal hyperplasia in mice following arterial injury?
Answers are grounded in this paper and cite their sources.
Mast cell stabilization with disodium cromoglycate reduces neointimal hyperplasia after arterial injury in mice, suggesting a potential therapeutic target to prevent restenosis after revascularization procedures.
mice, not only was the neointimal hyperplasia induced, but the neutrophil, macrophage, and T-cell populations were also present in these transplanted mice. To demonstrate the utility of MC as a target for therapy, we administered the MC stabilizing drug, disodium cromoglycate (DSCG) immediately following arterial injury and were able to show a reduction in neointimal hyperplasia in wild-type mice. These studies suggest a critical role for MC in inducing the conditions and coordinating the detrimental inflammatory response seen post-endothelial injury in arteries undergoing revascularization procedures, and by targeting the rapid MC degranulation immediately post-surgery with DSCG, this restenosis may become a preventable clinical complication.
No takes yet. Share an insight, caveat, or question.
Harper et al. (2023) studied Acute artery injury and neointimal hyperplasia. Disodium cromoglycate (DSCG) was evaluated on Neointimal hyperplasia. Administration of the mast cell stabilizing drug disodium cromoglycate immediately following arterial injury reduced neointimal hyperplasia in wild-type mice.
Synapse has enriched 10 related papers. Consider them for comparative context: